SCHEMBL2790027

SCHEMBL2790027

CN(CC(N)c1ccc(C(=O)Nc2ccncc2)cc1)C(=O)Cc1cccs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.51
ROCK1 Q13464 2/20 0.51
KDM4E B2RXH2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.42
POLB P06746 4/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
BLM P54132 1/20 0.42
ALDH1A1 P00352 1/20 0.41
NAMPT P43490 3/20 0.41
JAK2 O60674 1/20 0.41
TYK2 P29597 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
STAT3 P40763 1/20 0.40
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
NT5E P21589 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2794143 0.86 ROCK2 (0.57) ROCK2ROCK1KDM4EL3MBTL1LMNA
SCHEMBL2793940 0.85 ROCK2 (0.54) ROCK2ROCK1KDM4EL3MBTL1LMNA
SCHEMBL2792404 0.82 ROCK2 (0.51) ROCK2ROCK1KDM4EL3MBTL1LMNA
SCHEMBL2790582 0.82 ROCK2 (0.51) ROCK2ROCK1KDM4EL3MBTL1LMNA
SCHEMBL2791124 0.82 ROCK2 (0.51) ROCK2ROCK1KDM4EL3MBTL1LMNA
SCHEMBL2793235 0.82 ROCK2 (0.51) ROCK2ROCK1KDM4EL3MBTL1LMNA
SCHEMBL2791651 0.82 ROCK2 (0.53) ROCK2ROCK1KDM4EL3MBTL1LMNA
SCHEMBL2792675 0.82 ROCK2 (0.46) ROCK2ROCK1KDM4EL3MBTL1LMNA
SCHEMBL2794078 0.82 POLB (0.56) ROCK2ROCK1LMNAPOLBNPC1
SCHEMBL2790936 0.82 ROCK2 (0.50) ROCK2ROCK1KDM4EL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168102-A9 Amide Derivatives as Kinase Inhibitors DEVGEN NV (BE) 2010-07-01 US disclosed
US-20090118283-A1 Amide Derivatives as Kinase Inhibitors DEVGEN NV (BE) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168102-A9 Amide Derivatives as Kinase Inhibitors MAP3K1, CDK1, CDK2 ROCK2 528/4885ROCK1 414/4885KDM4E 4352/4885
US-20090118283-A1 Amide Derivatives as Kinase Inhibitors MAP3K1, CDK1, CDK2 ROCK2 528/4885ROCK1 414/4885KDM4E 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.